Results of 15-Year Experience in Liver Transplant for Hepatocellular Carcinoma.

Background: Liver transplant (LT) supposes a curative option for those patients with hepatocellular carcinoma (HCC) meeting the Milan criteria. Adjuvant therapies, such as transarterial chemoembolization (TACE), can prevent tumor progression. Our aim was to analyze the outcomes of patients who have been transplanted at our center and to assess the effectiveness of TACE in patients on the waiting list for LT.

Analysis of the Predictive Ability for Graft Loss and Mortality of Two Criteria for Early Allograft Dysfunction After Liver Transplantation.

Introduction: The current imbalance between available donors and potential recipients for orthotopic liver transplantation (OLT) has led to a liberalization of organ acceptance criteria, increasing the risk of post-transplant complications such as early allograft dysfunction (EAD). Consequently, we need accurate criteria to detect patients with early poor graft function to guide the strategies of management. We evaluated the usefulness of two frequently used criteria: the definition from Olthoff et al and the Model for Early Allograft Function (MEAF) scoring.

Analysis of Indications and Results in Liver Retransplantation: Is Late Retransplantation Worthwhile?

Background: Liver retransplantation (LrT) is the only therapeutic option for irreversible hepatic graft failure. Despite various improvements, its technical complexity entails a greater morbidity in the short and long term. The main goal of the study was to analyze the activity of LrT at our center, as well as its indications, timing, postoperative evolution, and the long-term survival of patients.

Liver Transplantation in Recipients With High Model for End-stage Liver Disease Score.

Objectives: The score in the Model of End-stage Liver Disease, or MELD, is a good indicator of the survival in patients on the liver transplant waiting list. In this study, an analysis is performed on the benefits of liver transplant on those patients with a very high MELD score and who thus start from a very severe baseline state that could affect the surgical outcome.

Materials And Methods: A prospective study was conducted on a cohort of 331 patients that received a liver transplant between 2002 and 2014.

Liver metastasis from colorectal cancer 12 years after liver transplantation.

Liver transplantation is an effective treatment for many liver diseases, with a 5-year survival of about 70 %. However, development of de novo malignancies in these immunocompromised patients is becoming a frequent complication medium term. The annual risk of developing a malignant tumor after a solid organ transplant is 2% .